MARKETS / NASDAQ / CBLL
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

CeriBell, Inc. CBLL

3 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$89.1M
▲ 36.1% vs FY2024
EPS · FY25
$-1.46
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-30.8%
Net margin · FY25
-60.0%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 89.1M
Revenue, FY2025 · full 3-year series below
Revenue Net income
0.0250.050.0750.10.1-0.120232025
0.0250.050.0750.10.1-0.120232025

The company lost 60 cents on every revenue dollar this year.

Per share
USD -1.46
Diluted EPS, FY2025
EPS
0.40.81.2-1.4620232025
0.40.81.2-1.4620232025

The company pays no cash dividend.

Profitability
-30.8%
Return on equity, FY2025
ROE
0.250.50.751-30.8%20232025
0.250.50.751-30.8%20232025
Operating margin-65.6%
Net margin-60.0%
Return on assets-25.4%

Each USD of equity lost 31 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.04B
Shares outstanding, FY2025
0.000.0420232025
0.000.0420232025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 195.8M
total assets, end of FY2025
Total assetsUSD 195.8M
EquityUSD 155.3M
CashUSD 40.5M
Gross debtUSD 19.8M
Net debtUSD -20.7M
Current ratio9.73×

The company holds more cash than debt.

History
3 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
Revenue $B
0.1
0.1
0.0
Operating income $B
−0.1
−0.0
−0.0
EBITDA $B
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
Net income $B
−0.1
−0.0
−0.0
EPS, diluted $
−1.46
−3.39
−5.56
Dividend / sh $
·
·
·
Payout %
·
·
·
ROE %
−30.8
−102.5
·
Shares out B
0.04
0.00
0.00

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
12 of 12
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed